NIKKEI 225
27,403.03 +20.47 (+0.07%) HANG SENG
22,280.73 -408.17 (-1.80%) CRUDE OIL
79.36 -0.32 (-0.40%) GOLD FUTURES
1,947.40 +1.80 (+0.09%) DOW
33,978.08 +28.68 (+0.08%) BTC-GBP
19,140.55 +307.46 (+1.63%)
Apontis Pharma AG (APPH.F)
| Previous close | 8.16 |
| Open | 8.46 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 8.00 - 8.46 |
| 52-week range | 5.90 - 18.00 |
| Volume | |
| Avg. volume | 371 |
| Market cap | 72.59M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 18.18 |
| EPS (TTM) | 0.44 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.70 |
- EQS Group
APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals
EQS-News: APONTIS PHARMA AG / Key word(s): Product LaunchAPONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals 29.11.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA: Number of announced market launches increases to ten Single Pills – Portfolio grows by two in-licensing deals Continuous expansion of the Single Pill portfolio to meet the target of at least 20 Single Pil
- EQS Group
APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets
EQS-News: APONTIS PHARMA AG / Key word(s): 9 Month figures/Quarterly / Interim StatementAPONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets 10.11.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA confirms 2022 forecast after successful nine-month period – Strong Single Pill pipeline to achieve medium-term targets Superiority of Single Pill therapy confirmed in
- EQS Group
APONTIS PHARMA announces cooperation to launch new Single Pill in Germany
EQS-News: APONTIS PHARMA AG / Key word(s): Alliance/Product LaunchAPONTIS PHARMA announces cooperation to launch new Single Pill in Germany 20.09.2022 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.APONTIS PHARMA announces cooperation to launch new Single Pill in Germany Single Pill for more efficient treatment of hypertension with potential peak sales of more than EUR 15.0 million Potential patient population of more than a million people Market launch pla
